India Pharma Outlook Team | Monday, 20 July 2026
India has cleared Fasenra expansion as AstraZeneca targets severe asthma patients with a wider treatment option.
The approval expands the use of Fasenra (benralizumab) in India, including younger patients with severe eosinophilic asthma. The move could improve access to advanced asthma care for patients who do not respond well to standard inhaled medicines.
AstraZeneca’s severe asthma treatment Fasenra has received a label expansion approval in India. The updated approval allows the drug to be used for children aged six years and above, along with adults and adolescents. The decision strengthens AstraZeneca’s position in the growing asthma care market.
Severe asthma remains a major health challenge for patients who continue to experience symptoms despite regular treatments. These patients often require additional therapies to control frequent asthma attacks and reduce hospital visits.
Fasenra is a biologic medicine designed for patients with eosinophilic asthma. It works by targeting eosinophils, which are immune cells linked to airway inflammation.
The expanded approval is expected to help doctors provide more treatment choices for eligible patients. Key benefits include:
Also Read: 10 Health Habits Doctors Swear By but Rarely Talk About
AstraZeneca’s asthma drug Fasenra has become an important therapy in the management of severe eosinophilic asthma globally. The company has focused on expanding access to biologic medicines for patients with difficult-to-control respiratory conditions.
The active ingredient in Fasenra, benralizumab, is an antibody therapy that targets the IL-5 receptor alpha pathway. This helps reduce eosinophil levels and may improve asthma control.
The company believes the expanded label will support more patients who need advanced therapies. It also reflects the growing demand for personalized treatments in respiratory care.
Eosinophilic asthma is a specific type of asthma linked with high levels of eosinophils in the blood and airways. These cells can increase inflammation and trigger repeated asthma attacks.
Traditional inhaled treatments may not provide enough control for some patients. Biologic therapies like Fasenra are developed for these difficult cases.
The India approval could benefit patients who:
With this label expansion, AstraZeneca aims to increase the availability of benralizumab for severe asthma patients across age groups in India. The move marks another step toward improving access to advanced respiratory treatments.
